Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment
- PMID: 38765466
- PMCID: PMC11099334
- DOI: 10.1016/j.jcte.2024.100344
Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment
Abstract
Cystic fibrosis (CF) has been traditionally viewed as a disease that affects White individuals. However, CF occurs among all races, ethnicities, and geographic ancestries. The disorder results from mutations in the CF transmembrane conductance regulator (CFTR). Varying incidence of CF is reported among Black, Indigenous, and People of Color (BIPOC), who typically exhibit worse clinical outcomes. These populations are more likely to carry rare CFTR variants omitted from newborn screening panels, leading to disparities in care such as delayed diagnosis and treatment. In this study, we present a case-in-point describing an individual of Gambian descent identified with CF. Patient genotype includes a premature termination codon (PTC) (c.2353C>T) and previously undescribed single nucleotide deletion (c.1970delG), arguing against effectiveness of currently available CFTR modulator-based interventions. Strategies for overcoming these two variants will likely include combinations of PTC suppressors, nonsense mediated decay inhibitors, and/or alternative approaches (e.g. gene therapy). Investigations such as the present study establish a foundation from which therapeutic treatments may be developed. Importantly, c.2353C>T and c.1970delG were not detected in the patient by traditional CFTR screening panels, which include an implicit racial and ethnic diagnostic bias as these tests are comprised of mutations largely observed in people of European ancestry. We suggest that next-generation sequencing of CFTR should be utilized to confirm or exclude a CF diagnosis, in order to equitably serve BIPOC individuals. Additional epidemiologic data, basic science investigations, and translational work are imperative for improving understanding of disease prevalence and progression, CFTR variant frequency, genotype-phenotype correlation, pharmacologic responsiveness, and personalized medicine approaches for patients with African ancestry and other historically understudied geographic lineages.
Keywords: African; Cystic fibrosis; Cystic fibrosis-related diabetes; Diagnosis; Genetics; Newborn screening.
© 2024 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures






Similar articles
-
The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine.J Genet Couns. 2020 Aug;29(4):607-615. doi: 10.1002/jgc4.1271. Epub 2020 Mar 30. J Genet Couns. 2020. PMID: 32227567
-
Detection of disease-causing CFTR variants in state newborn screening programs.Pediatr Pulmonol. 2023 Feb;58(2):465-474. doi: 10.1002/ppul.26209. Epub 2022 Oct 25. Pediatr Pulmonol. 2023. PMID: 36237137 Free PMC article.
-
Genetic analysis of Rwandan patients with cystic fibrosis-like symptoms: identification of novel cystic fibrosis transmembrane conductance regulator and epithelial sodium channel gene variants.Chest. 2009 May;135(5):1233-1242. doi: 10.1378/chest.08-2246. Epub 2008 Nov 18. Chest. 2009. PMID: 19017867
-
One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.Cells. 2022 Jun 8;11(12):1868. doi: 10.3390/cells11121868. Cells. 2022. PMID: 35740997 Free PMC article. Review.
-
Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75. doi: 10.1345/aph.1R076. Epub 2012 Jun 26. Ann Pharmacother. 2012. PMID: 22739718 Review.
Cited by
-
Facilitators and Barriers to Increasing Equity in Cystic Fibrosis Newborn Screening Algorithms.Pediatr Pulmonol. 2025 Jan;60(1):e27449. doi: 10.1002/ppul.27449. Epub 2024 Dec 20. Pediatr Pulmonol. 2025. PMID: 39704065
-
The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota.Microbiology (Reading). 2025 Apr;171(4):001553. doi: 10.1099/mic.0.001553. Microbiology (Reading). 2025. PMID: 40202901 Free PMC article. Review.
-
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251323194. doi: 10.1177/17534666251323194. Epub 2025 Mar 31. Ther Adv Respir Dis. 2025. PMID: 40163448 Free PMC article. Review.
-
Recent developments in cystic fibrosis drug discovery: where are we today?Expert Opin Drug Discov. 2025 May;20(5):659-682. doi: 10.1080/17460441.2025.2490250. Epub 2025 Apr 13. Expert Opin Drug Discov. 2025. PMID: 40202089 Review.
References
-
- Stalvey M.S., Clines G.A. Cystic fibrosis-related bone disease: insights into a growing problem. Curr Opin Endocrinol Diabetes Obes. 2013;20:547–552. doi: 10.1097/01.med.0000436191.87727.ec. - DOI - PMC - PubMed
-
- Walkowiak J., Herzig K.H., Witt M., Pogorzelski A., Piotrowski R., Barra E., et al. Analysis of exocrine pancreatic function in cystic fibrosis: one mild CFTR mutation does not exclude pancreatic insufficiency. Eur J Clin Invest. 2001;31:796–801. doi: 10.1046/j.1365-2362.2001.00876.x. - DOI - PubMed
-
- Moran A., Brunzell C., Cohen R.C., Katz M., Marshall B.C., Onady G., et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33:2697–2708. doi: 10.2337/dc10-1768. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources